Regulatory Regulatory round-up: A month of key FDA approvals for cancer drugs Pharmaceutical TechnologyFour cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.OncologyRead full story pharminent May 14, 2026 (Last updated: May 14, 2026) Pharmaceutical Technology Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ECO 2026: gut hormone signals differ in T1D with obesityNext: FDA hands BeOne, Taiho approvals for blood cancers Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
